Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
Björn Dahlöf(Sahlgrenska University Hospital), Hans Wedel(Sahlgrenska University Hospital), Krister Kristiansson(MSD (Sweden)), Lars Lindholm(Umeå University), Per Omvik(Haukeland University Hospital), Ulf dé Fairé(Karolinska Institutet), Markku S. Nieminen(Cornell University), Ole Lederballe‐Pedersen(Regionshospitalet Viborg), Sverre E. Kjeldsen(Oslo University Hospital), Hans Ibsen(Glostrup Hospital), Frej Fyhrquist(Helsinki University Hospital), Richard B. Devereux(NewYork–Presbyterian Hospital), Suzanne Oparil(University of Alabama at Birmingham), Stevo Julius, Gareth Beevers(Birmingham City Hospital)
Cited by 5,417
Related Papers
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
|The Lancet|1998|5.8k
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
|New England Journal of Medicine|2007|4.6k
Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery
|New England Journal of Medicine|2004|4.5k